Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK105 plus Anlotinib and Radiotherapy in MGMT Unmethylated Glioblastoma
NCT05033587Phase 2Unknown
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Sep 2021
- Primary completion
- May 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of penpulimab, anlotinib in glioblastoma (GBM), sponsored by Nanjing Drum-Tower Hospital. Status: unknown.
02
Drugs
penpulimabanlotinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05033587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05033587.